BRISBANE, CALIFORNIA, April 28, 2026
CareDx Inc. has announced a definitive agreement to acquire Naveris, marking a significant expansion of its precision medicine testing services into specialty oncology. The transaction includes an upfront payment of $160 million, with up to $100 million in additional milestone-based payments, highlighting strong confidence in Naveris’ commercial-stage molecular diagnostics platform. This strategic acquisition strengthens CareDx’s position in high-growth oncology diagnostics, particularly in minimal residual disease (MRD) surveillance, a rapidly evolving area in cancer care with an estimated $4.5 billion total addressable market (TAM).
Advanced Liquid Biopsy Platform for Cancer Monitoring
At the core of the acquisition is Naveris’ innovative liquid biopsy platform based on Tumor Tissue Modified Viral (TTMV®) DNA, which enables highly sensitive detection of cancer-related viral DNA fragments in the bloodstream. This blood-based diagnostic technology is designed for human papillomavirus (HPV)-driven cancers, including head and neck and anal cancers, supporting early detection, treatment monitoring, and post-therapy surveillance.
The platform’s tumor-naïve approach allows clinicians to track molecular residual disease (MRD) without requiring prior tumor tissue samples, offering a significant clinical advantage over conventional diagnostic methods. With more than 130,000 commercial tests performed and Medicare reimbursement secured since 2023, Naveris’ technology demonstrates strong clinical adoption and real-world validation, positioning it as a leader in precision oncology diagnostics.
Strong Financial Growth and Strategic Synergies
Advertisement
Naveris reported $34 million in revenue in 2025, with projected annual growth of 30–40% over the next three years, reflecting robust demand for non-invasive cancer monitoring solutions. In the first quarter of 2026 alone, the company generated approximately $12 million in revenue with strong gross margins of 65%, underscoring its commercial scalability and operational efficiency.
CareDx expects the acquisition to be neutral to its 2026 adjusted EBITDA guidance, demonstrating a disciplined financial approach while pursuing strategic expansion. The integration of Naveris’ platform with CareDx’s existing capabilities in molecular diagnostics, digital health, and patient solutions is expected to create significant synergies, enhancing clinical workflows and expanding access to precision medicine technologies across oncology and transplant care.
Transforming Cancer Care Through Precision Medicine
The acquisition reflects a broader shift in the healthcare industry toward personalized, data-driven cancer management, where liquid biopsy and MRD testing play a critical role in improving patient outcomes. Naveris’ flagship NavDx® test, a clinically validated circulating tumor DNA assay, enables earlier detection of cancer recurrence and more precise disease monitoring, helping clinicians make timely, informed treatment decisions.
From a GxP perspective, the platform operates within CLIA-certified and CAP-accredited laboratories, ensuring compliance with high-quality regulatory standards in diagnostic testing. By combining CareDx’s leadership in transplant genomics with Naveris’ oncology expertise, the company is well positioned to drive innovation at the intersection of diagnostics and precision medicine, ultimately advancing next-generation cancer care solutions. The transaction is expected to close in Q3 2026, subject to regulatory approvals and customary conditions, marking a pivotal step in CareDx’s long-term growth strategy.
Source: CareDx, Naveris press release
